Results 161 to 170 of about 25,087 (209)

Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study.

Acta Haematol
Kasner MT, Courtenay-Luck N, DiNardo C, Post SM, Baratam P, Magrath GN, Nakamura T, Fujii A, Prados S, Honda N, Mcbride M, Edwards-Holmes P, Stuart R.   +12 more
europepmc   +1 more source

Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches. [PDF]

Blood Res
Lima K, Nogueira FL, Reis-Silva CSM, de Cássia Cavaglieri R, Costa-Lotufo LV, Machado-Neto JA, Rego EM.   +6 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

Case Report: FIA plus venetoclax in a patient on hemodialysis. [PDF]

Front Oncol
Herstein JE, Marx KR, Savoy JM, Jen WY, Yilmaz M, Short NJ, Issa GC, Ravandi F, Kadia TM, Daver NG, DiNardo CD.   +10 more
europepmc   +1 more source

Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study. [PDF]

Ann Hematol
Li Y, Shang Y, Liu K, Liu Y, Lin D, He J, Li J, Zeng Y, Wei H, Yan Z, Mi Y.   +10 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. [PDF]

Biomedicines
Joshi U, Shallis RM.
europepmc   +1 more source

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL). [PDF]

Cancer Biol Ther
Lei H, Zhang Y, Zheng H, Shi P, Wei X, Guo X.   +5 more
europepmc   +1 more source

Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors. [PDF]

Front Pharmacol
Zhang X, Peng Y, Tian Y, Chen S, Jia Y, Liu M, Zhang L.   +6 more
europepmc   +1 more source

15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study. [PDF]

Cancers (Basel)
Lai B, Mei C, Yan X, Chen L, Wang Y, Sheng L, Tang S, Mao L, Zhang P, Sun Y, Xie W, Zhou, Mai W, Wang H, Ma L, Lou Y, Wu W, Jiang H, Zhang J, Ye B, Tong H, Ouyang G.   +21 more
europepmc   +1 more source